缩宫素受体在子宫内膜异位症子宫结合带中的表达

发布时间：2018-05-14 13:37

  本文选题：子宫内膜异位症(EMS) + 缩宫素受体(OTR)　； 参考：《中华生殖与避孕杂志》2017年03期

【摘要】：目的探讨缩宫素受体(OTR)在子宫内膜异位症(EMS)子宫结合带中的表达水平及临床意义。方法收集因EMS行子宫切除术的子宫结合带蜡块组织43例为EMS组,其中增生期25例,分泌期18例。收集同期因宫颈癌、卵巢癌或宫颈上皮内瘤变Ⅲ级行子宫切除术的患者子宫结合带蜡块组织54例为对照组,其中增生期28例,分泌期26例。采用免疫组织化学方法检测各组子宫结合带组织中OTR的表达水平。结果对照组增生期子宫结合带OTR(0.156±0.056)表达高于分泌期子宫结合带OTR(0.126±0.030),差异有统计学意义(P=0.017)。EMS组增生期(0.205±0.106)和分泌期(0.187±0.070)子宫结合带OTR含量表达无统计学差异(P=0.523),且含量分别高于对照组(0.156±0.056,0.126±0.030)相应月经周期子宫结合带OTR的表达,差异均有统计学意义(P=0.043,P=0.002)。EMS组子宫结合带中OTR的表达水平与痛经程度呈正相关(r=0.836,P0.05)。结论 EMS子宫结合带缩宫素受体异常高表达,表明其可能和EMS的发病及引起的相关症状有关。
[Abstract]:Objective to investigate the expression and clinical significance of oxytocin receptor (OTRR) in uterine binding zone of endometriosis. Methods 43 cases of uterine binding paraffin tissue underwent hysterectomy with EMS were divided into EMS group (25 cases in proliferative phase and 18 cases in secretory phase). Fifty-four cases of uterine binding waxed tissue were collected as control group, 28 cases in proliferative phase and 26 cases in secretory phase. The patients with cervical cancer, ovarian cancer or cervical intraepithelial neoplasia grade 鈪，

本文编号：1888063